TY - JOUR
T1 - Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor
AU - Wijeyewickrema, Lakshmi C.
AU - Lameignere, Emilie
AU - Hor, Lilian
AU - Duncan, Renee C.
AU - Shiba, Toshikazu
AU - Travers, Richard J.
AU - Kapopara, Piyushkumar R.
AU - Lei, Victor
AU - Smith, Stephanie A.
AU - Kim, Hugh
AU - Morrissey, James H.
AU - Pike, Robert N.
AU - Conway, Edward M.
N1 - Funding Information:
R.N.P. was supported by the National Health and Medical Research Council of Australia and the Australian Research Council. H.K. was supported by an operating grant and a Clinician-Scientist Award from the Canadian Institutes of Health Research. E.M.C. was supported by grants from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Canada Foundations for Innovation. E.M.C. holds a CSL Behring Research Chair and a Tier 1 Canada Research Chair in Endothelial Cell Biology, and is an Adjunct Scientist with the Canadian Blood Services. Laboratory studies were supported by a grant from the National Institutes of Health National Heart, Lung, and Blood Institute (R01 HL047014) (J.H.M.). None of the funders had any input into the design of the experiments, the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit it for publication.
PY - 2016/9/29
Y1 - 2016/9/29
N2 - The complement system plays a key role in innate immunity, inflammation, and coagulation. The system is delicately balanced by negative regulatory mechanisms that modulate the host response to pathogen invasion and injury. The serpin, C1-esterase inhibitor (C1-INH), is the only known plasma inhibitor of C1s, the initiating serine protease of the classical pathway of complement. Like other serpin-protease partners, C1-INH interaction with C1s is acceleratedby polyanions such as heparin. Polyphosphate (polyP) is a naturally occurring polyanion with effects on coagulation and complement. We recently found that polyP binds to C1-INH, prompting us to consider whether polyP acts as a cofactor for C1-INH interactions with its target proteases. We show that polyP dampens C1s-mediated activation of the classical pathway in a polymer length- and concentration-dependent manner by accelerating C1-INH neutralization of C1s cleavage of C4 and C2. PolyP significantly increases the rate of interaction between C1s and C1-INH, to an extent comparable to heparin,with an exosite on the serine protease domain of the enzyme playing a major role in this interaction. In a serum-based cell culture system, polyP significantly suppressed C4d deposition on endothelial cells, generated via the classical and lectin pathways. Moreover, polyP and C1-INH colocalize in activated platelets, suggesting that their interactions are physiologically relevant. In summary, like heparin, polyPis a naturally occurring cofactor for theC1s:C1-INHinteractionandthus animportant regulator ofcomplement activation.The findingsmay providenovel insights into mechanisms underlying inflammatory diseases and the development of new therapies.
AB - The complement system plays a key role in innate immunity, inflammation, and coagulation. The system is delicately balanced by negative regulatory mechanisms that modulate the host response to pathogen invasion and injury. The serpin, C1-esterase inhibitor (C1-INH), is the only known plasma inhibitor of C1s, the initiating serine protease of the classical pathway of complement. Like other serpin-protease partners, C1-INH interaction with C1s is acceleratedby polyanions such as heparin. Polyphosphate (polyP) is a naturally occurring polyanion with effects on coagulation and complement. We recently found that polyP binds to C1-INH, prompting us to consider whether polyP acts as a cofactor for C1-INH interactions with its target proteases. We show that polyP dampens C1s-mediated activation of the classical pathway in a polymer length- and concentration-dependent manner by accelerating C1-INH neutralization of C1s cleavage of C4 and C2. PolyP significantly increases the rate of interaction between C1s and C1-INH, to an extent comparable to heparin,with an exosite on the serine protease domain of the enzyme playing a major role in this interaction. In a serum-based cell culture system, polyP significantly suppressed C4d deposition on endothelial cells, generated via the classical and lectin pathways. Moreover, polyP and C1-INH colocalize in activated platelets, suggesting that their interactions are physiologically relevant. In summary, like heparin, polyPis a naturally occurring cofactor for theC1s:C1-INHinteractionandthus animportant regulator ofcomplement activation.The findingsmay providenovel insights into mechanisms underlying inflammatory diseases and the development of new therapies.
UR - http://www.scopus.com/inward/record.url?scp=84990053118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990053118&partnerID=8YFLogxK
U2 - 10.1182/blood-2016-02-699561
DO - 10.1182/blood-2016-02-699561
M3 - Article
C2 - 27338096
AN - SCOPUS:84990053118
VL - 128
SP - 1766
EP - 1776
JO - Blood
JF - Blood
SN - 0006-4971
IS - 13
ER -